T3D Therapeutics Overview

  • Founded

  • 2013

Founded
  • Status

  • Private

  • Employees

  • 14

Employees
  • Latest Deal Type

  • Series C

  • Latest Deal Amount

  • $6M

  • Investors

  • 4

T3D Therapeutics General Information

Description

Developer of a novel drug therapy designed to offer a transformational approach that can stop or reverse the course of Alzheimer's disease. The company's drug is an orally-delivered once-a-day medicine that targets both the brain 'starvation' and neurodegeneration of Alzheimer's disease and helps in treating multiple manifestations of the disease, enabling Alzheimer's patients to have access to drugs that improve memory, motor function, and cognition.

Contact Information

Website
www.t3dtherapeutics.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • Post Office Box 13628
  • 68 T.W. Alexander Drive, Research Triangle Park
  • Durham, NC 27709
  • United States
+1 (919) 000-0000

T3D Therapeutics Timeline

2020202120222023
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

T3D Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
13. Later Stage VC (Series C) 03-Sep-2022 $6M 000.00 0000 Completed Clinical Trials - Phase 2
12. Grant 15-Sep-2020 00000 000.00 Completed Clinical Trials - General
11. Grant 01-Aug-2020 000 000.00 Completed Clinical Trials - General
10. Later Stage VC (Series B) 04-Nov-2019 0000 000.00 Completed Clinical Trials - General
9. Grant 20-May-2019 000 000.00 Completed Clinical Trials - General
8. Grant 01-May-2019 00.000 000.00 Completed Clinical Trials - General
7. Later Stage VC (Series B) 10-Mar-2018 000 000.00 0000 Completed Clinical Trials - General
6. Early Stage VC (Series A3) 11-Mar-2016 00.000 00.000 0000 Completed Clinical Trials - General
5. Grant 24-Mar-2015 $1.91M $1.4M Completed Clinical Trials - General
4. Debt - General 31-Jul-2014 $250K $1.4M Completed Startup
To view T3D Therapeutics’s complete valuation and funding history, request access »

T3D Therapeutics Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series C 0,000,000 00.000000 00 00 00 00 00 0.000
Series B 0,000,000 00.000000 00
Series A3 0,000,000 00.000000 00 00 00 00 00 0.000
Series A2 482,332 $0.001000 6% $1.5 $1.5 1x $1.5 2.88%
Series A1 404,628 $0.001000 6% $1.08 $1.08 1x $1.08 2.42%
To view T3D Therapeutics’s complete cap table history, request access »

T3D Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a novel drug therapy designed to offer a transformational approach that can stop or reverse the course of A
Drug Discovery
Durham, NC
14 As of 2022
000.00
000 0000-00-00
00000000000 000.00

000000

nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa q
0000 000000000
Clarksville, MD
0 As of 0000
00.000
00000000000

000 00

t in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint
0000 000000000
Boston, MA
0 As of 0000
000.00
000000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

T3D Therapeutics Competitors (35)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
NeuroNascent Venture Capital-Backed Clarksville, MD 0 00.000 00000000000
000 000000 Venture Capital-Backed Boston, MA 0 000.00 000000000000 000.00
000000000 Venture Capital-Backed New York, NY 00 00000 00000000000 00000
0000000 Venture Capital-Backed Singapore, Singapore 00 00000 00000000000 00000
0000000 0000000000 Venture Capital-Backed South San Francisco, CA 00 00000 00000000000 00000
You’re viewing 5 of 35 competitors. Get the full list »

T3D Therapeutics Patents

  • 11

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 000

    Granted

  • 1

    Pending

  • 000

    Expiring in next 12 mo

T3D Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210369680-A1 Methods of treating diseases and disorders resulting from beta coronavirus infection Pending 29-Apr-2020 0000000000 0
US-20180153859-A1 Methods of treating or preventing cognitive impairment using indane acetic acid derivatives based on apoe4 genotype Inactive 02-Dec-2016 0000000000
EP-3548023-A1 Methods of dose administration for treating or preventing cognitive impairment using indane acetic acid derivatives Inactive 02-Dec-2016 0000000000
EP-3548023-A4 Methods of dose administration for treating or preventing cognitive impairment using indane acetic acid derivatives Inactive 02-Dec-2016 0000000000 0
US-20180153860-A1 Methods of dose administration for treating or preventing cognitive impairment using indane acetic acid derivatives Inactive 02-Dec-2016 A61K31/421 0
To view T3D Therapeutics’s complete patent history, request access »

T3D Therapeutics Executive Team (4)

Name Title Board Seat Contact Info
Stanley Chamberlain Ph.D Co-Chief Executive Officer & Chief Scientific Officer
John Didsbury Ph.D Founder, Chairman, President & Co-Chief Executive Officer
Warren Strittmatter MD Chief Medical Officer & CSO
Barry Buzogany JD Consultant & Board Member
To view T3D Therapeutics’s complete executive team members history, request access »

T3D Therapeutics Board Members (7)

Name Representing Role Since
Barry Buzogany JD Self Consultant & Board Member 000 0000
Charles Lineberry Ph.D Self Board Member 000 0000
David Keim Self Board Member 000 0000
Donald Parker Self Board Member 000 0000
John Didsbury Ph.D T3D Therapeutics Founder, Chairman, President & Co-Chief Executive Officer 000 0000
You’re viewing 5 of 7 board members. Get the full list »

T3D Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

T3D Therapeutics Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Alzheimers Association Corporation 000 0000 000000 0
National Institute On Aging Government Minority 000 0000 000000 0
National Institutes of Health Government 000 0000 000000 0
U.S. Department of Health and Human Services Government 000 0000 000000 0
To view T3D Therapeutics’s complete investors history, request access »

Ready to get started?

Request a free trial